EFFICACY OF ISOXSUPRINE HYDROCHLORIDE IN THE MANAGEMENT OF GRADE III PRE-PARTUM CERVICO-VAGINAL PROLAPSE IN BUFFALOES

Abstract

Pre-partum cervico-vaginal prolapse is an important reproductive disorder of advanced pregnant buffaloes that adversely affects maternal health and productivity. The present study evaluated the therapeutic efficacy of different doses of Isoxsuprine hydrochloride in the management of Grade III pre-partum cervico-vaginal prolapse in buffaloes. The study was conducted at the Department of Animal Reproduction, Gynaecology and Obstetrics, College of Veterinary and Animal Sciences, Udgir, Maharashtra. Thirty-two advanced pregnant buffaloes (8–10 months gestation) were randomly allocated into four groups of eight animals each. All animals were treated by reduction, reposition and retention (RRR) along with calcium magnesium borogluconate administration. Group I served as the control, while Groups II, III and IV received Isoxsuprine HCl intramuscularly at doses of 25 mg, 50 mg and 100 mg, respectively. Clinical observations, straining activity, physiological parameters, serum minerals and progesterone levels were recorded before and after treatment.

The prevalence of pre-partum cervico-vaginal prolapse was 8.0 per cent among obstetrical cases. Isoxsuprine treatment significantly reduced the frequency and severity of straining, with the 100 mg dose producing the greatest improvement. Significant increases in serum calcium, phosphorus and progesterone levels following treatment indicated correction of metabolic imbalance. Physiological parameters remained within normal limits throughout the study. No recurrence was observed in animals treated with higher doses of Isoxsuprine. The findings demonstrate that combined therapy comprising RRR, calcium magnesium borogluconate and Isoxsuprine hydrochloride effectively manages pre-partum cervico-vaginal prolapse in buffaloes. Among the regimens evaluated, 100 mg Isoxsuprine HCl was the most effective, indicating a clear dose-dependent therapeutic response.